Cephalon Plans To File Patent Suit Vs Sandoz Over Provigil ANDA

Law360, New York (May 11, 2004, 12:00 AM EDT) -- Cephalon Inc. said in a regulatory filing to the U.S. Securities and Trade Commission that it plans to sue Sandoz Inc. over its Abbreviated New Drug Application (ANDA) for a generic form of modafinil, the active drug substance in its narcolepsy drug Provigil.

Cephalon is in the process of evaluating Sandoz's filing with the Food and Drug Administration and plans shortly to file a patent infringement lawsuit against Sandoz, according to the company’s quarterly filing to the SEC.

Generics drug applicants must include with ANDAs a...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.